Wells Fargo downgraded Penumbra from Overweight to Equal Weight and set a new price target of $150.00 from $289.00 previously
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/14/2025 | $320.00 | Buy | BofA Securities |
| 1/21/2025 | $305.00 | Buy | UBS |
| 12/17/2024 | $275.00 | Outperform | Oppenheimer |
| 12/11/2024 | $190.00 → $275.00 | Equal Weight → Overweight | Wells Fargo |
| 9/18/2024 | $238.00 | Buy | Stifel |
| 9/3/2024 | $263.00 | Outperform | Leerink Partners |
| 7/31/2024 | $289.00 → $150.00 | Overweight → Equal Weight | Wells Fargo |
| 7/31/2024 | $165.00 → $178.00 | Buy → Neutral | Citigroup |
BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00
UBS initiated coverage of Penumbra with a rating of Buy and set a new price target of $305.00
Oppenheimer initiated coverage of Penumbra with a rating of Outperform and set a new price target of $275.00
ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "
STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolism ALAMEDA, Calif., June 16, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial enrolled 100 patients to evaluate computer assisted vacuum thrombectomy (CAVT) using Penumbra's Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for the treatment of acute
ALAMEDA, Calif., June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolizationii. "We've engineered Ruby XL to deliver more volume per coil than any other coil on the market, which may result in cost savings," said Shruthi Naraya
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
SD - Penumbra Inc (0001321732) (Filer)
8-K - Penumbra Inc (0001321732) (Filer)
144 - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G - Penumbra Inc (0001321732) (Subject)
ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "
ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income
ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the
Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i
SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma